



# Ronnie Aronson MD, FRCPC, FACE

\* Ronnie Aronson provides medical services through Dr. Ronnie Aronson Medicine Professional Corporation

Bayview 1929 Bayview Avenue, Suite 107, 125, Toronto, Ontario, M4G 3E8, Canada

Tel (416) 645-2929

## CURRICULUM VITAE

### Education

2018-2020	ICH-GCP Certificate	Transcelerate
Mar 2015	Advanced Cardiac Life Support (ACLS)	ACLS Certification Institute
1998	Fellowship	American College of Endocrinology
1995	Certification, Endocrinology & Metabolism	Royal College of Physicians Canada, American Board of Internal Medicine
1994	Fellowship, Internal Medicine	Royal College of Physicians Canada, American Board of Internal Medicine
1990	Doctor of Medicine	University of Toronto, Toronto ON

### Professional Activities

Oct 2015-Present	Chief Medical Officer	LMC Diabetes & Endocrinology
1997-Present	Principal/Sub-Investigator	LMC Clinical Research Inc.
1997-2015	Executive Director	LMC Diabetes & Endocrinology
1995-2001	Staff Endocrinologist	Oakville Trafalgar Memorial Hospital, Oakville ON

### Publications\*

- **Aronson R**, Brown R, Li A, Riddell M. Optimal insulin correction factor in post-high-intensity exercise hyperglycemia in adults with type 1 diabetes. The FIT study. *Diabetes Care* 2019. Doi.org/10.2337/dc18-475
- Potashner D, Brown R, Li Aihua, Riddell M, **Aronson R**. Paradoxical rise in hypoglycemia symptoms with development of hyperglycemia during high-intensity interval training in type 1 diabetes. *Diabetes Care* 2019 Oct;42(10):2011-2014.
- Aronson R, Li Aihua, Brown R, Walker A, Lyons A, Orzech N. Optimizing diabetes self-management using the novel Skills, Confidence, and Preparedness Index (SCPI). *Diabetes Care*. 2019 Oct;42(10):1873-1878.
- **Aronson R**, Brown R, Abitbol A, Bajaj HS, Goldenberg R, Khandwala H, Abdel-Salam S. Patient Reported Outcomes following initiation of glucagon-like peptide-1 receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study. *Diabetes Res Clin Pract*. 2019 Aug 22;156:107820.
- **Aronson R**, Umpierrez G, Stager W, Kovatchev B. Insulin glargine/lixisenatide fixed-ratio combination improves glycemic variability and control without increasing hypoglycemia. *Diab Obes Metab* 2018. DOI: 10.1111/dom.13580
- Pedersen-Bjergaard U, Alsfiri S, **Aronson R**, et al. Comparison of the HAT study, the largest global hypoglycemia study to date, with similar large real-world studies. *Diab Ob Metab* 2018. Doi: 10.1111/dom13588
- Bajaj H, Brown R, Bhullar L, Sohi N, Kalra S, **Aronson R**. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. *Diabet Metab* 2018. <http://dio.org/10.1016/j.diabet.2018.08.001>
- **Aronson R**, Frias J, Goldman A, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. *Diabetes Obes Metab* 2018. In press. DOI:10.1111/dom.13251
- **Aronson R**, Galstyan G, Goldfracht M, et al. Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. *Diabetes Res Clin Pr* 2018;138:35-43. DOI 10.1016/j.diabres.2018.01.007
- Bajaj H, Ye C, Jain E, Venn K, Stein E, **Aronson R**. Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study). *Diabetes Obes Metab* 2018;20:195-199
- **Aronson R**, Brown RE, et al. Assessment of self-management in patients with diabetes using the novel LMC Skills, Confidence and Preparedness Index (SCPI). *Diabetes Res Clin Prac* 2017. doi: <https://doi.org/10.1016/j.diabres.2017.10.028>
- Brown R, Gupta N, **Aronson R**. Effect of dapagliflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in Canada: a retrospective cohort analysis. *Diabetes Technology & Therapeutics* 2017; 19(11): 685-691. Doi: 10.1089/dia.2017.0134
- Beck RB, Riddlesworth TD, et al., **Aronson R**, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes. *Ann Intern Med* 2017. doi:10.7326/M16-2855
- Khunti K, Alsfiri S, **Aronson R**, et al. Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. *Diabetes Res Clin Pract* 2017;130:121-9 doi: 10.1016/j.diabres.2017.05.004
- **Aronson R**, Goldenberg R, et al. The Canadian Hypoglycemia Assessment Tool Program. *Can J Diabetes* 2017. Published online ahead of print doi: 10.1016/j.cjcd.2017.01.007
- Metzger M, Castaneda J, et al., **Aronson R**, et al. Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: an analysis from the Opt2mise randomized trial. *Diabetes Obes Metab* 2017. DOI: 10.1111/DOM.12960
- Mbuagbaw L, **Aronson R**, et al. The LMC Skills, Confidence & Preparedness Index (SCPI): development and evaluation of a novel tool for assessing self-management in patients with diabetes. *Health Qual Life Outcomes* 2017;15: 27. Doi: 10.1186/s12955-017-0606-z.
- Bajaj H, Venn K, Ye C, Patrick A, Kalra S, Khandeala H, Aslam N, Twum-Barima D, **Aronson R**. Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study). *Diabetes Care* 2017 Feb; 40(2):194-200. Doi: 10.2337/dc16-1582.
- Bajaj H, Venn K, Ye C, **Aronson R**. Randomized Trial of Long-Acting Insulin Glargine Titration Web Tool (LTHome) Versus Enhanced Usual Therapy of Glargine Titration (INNOVATE Trial). *Diabetes Technology & Therapeutics* 2016;18:610-615
- **Aronson R**, Orzech N, Ye C, Brown R, Goldenberg R, Brown V. Specialist-led Diabetes Registries and Prevalence of Poor Glycemic Control in Type 2 Diabetes: The Diabetes Registry Outcomes Project for A1c Reduction (DROP A1C). *Diabetes Care* 2016;39(10):1711-1717. Doi: 10.2337/dc15-2666.
- Khunti K, Alsfiri S, **Aronson R**, et al. Rates and predictors of hypoglycaemia in 27,585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. *Diabetes Obes Metab* 2016;18:907-15
- Rosenstock J, **Aronson R**, et al. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled With Oral Agents: The LixiLan-O Randomized Trial. *Diabetes Care* 2016;39(11):2026-35
- Bajaj H, **Aronson R**, et al. The Need Associated with Diabetes Primary Care and the Impact of Referral (the NADIR Study). *Can J Diabetes* 2016;40:120-5
- Rosenstock J, Guerci B, Hanefeld M, Gentile S, **Aronson R**, et al. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. *Diabetes Care* 2016;39(8):1318-28. Doi: 10.2337/dc16-0014.
- **Aronson R**, Reznik Y, Conget I, et al. Sustained efficacy of insulin pump therapy, compared with multiple daily injections, in type 2 diabetes... *Diabetes Obes Metab* 2016;18:500-7
- **Aronson R**. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. *Curr Med Res Opin* 2015;31:901-11
- **Aronson R**. The Functionally Refractory Patient in Diabetes – Prevalence and Predictors within Specialist Care Registries. *US Endocrinology* 2015;11(1):30-1
- **Aronson R**, Orzech N, Ye C, Goldenberg R, Brown V. Specialist-led Diabetes Registries and Predictors of Poor Glycemic Control in Type 2 Diabetes: Insights into the Functionally Refractory Patient from the LMC Diabetes Registry Database. *J Diabetes* 2016;8:76-85

### Clinical Trials & Research Activities

- |           |   |
|-----------|---|
| 2016-2020 | B1521022 (Pfizer), B1481022 (Pfizer), B1481038 (Pfizer), APD35-G000-401(Eisai), MK8835-002 (Merck), EFC12404/405 (Sanofi-aventis), B1481045 (Pfizer), NN9211-3919 (Novo Nordisk), EFC13799 (Sanofi-aventis), 200977 (GSK), 28431754DNE3001 (Janssen), 28431754DIA2004 (Janssen), D5881C00004 (AstraZeneca), LX4211.309 (Lexicon), DK101108 (Joslin Diabetes), BDT-SMART02 (BD Technologies), LX4211.312 (Lexicon), D1690C00024 (AstraZeneca), NN9828-4150 (Novo Nordisk), B4801010 (Pfizer), PTL901148 (Dexcom), ESR-14-10353 (PHRI) FIT (LMC Diabetes), NN1218-3854 (Novo Nordisk), EFC13834 (Sanofi), LPS14347 (Sanofi), DRI13940 (Sanofi), CTP-0024 (Senseonics), EFC14837 (Sanofi), D5670C00004 (AstraZeneca), GS-US-402-1852 (Gilead), NN9828-4150 (Novo Nordisk), NN1250-4252 (Novo Nordisk), NN1218-4113 (Novo Nordisk), C1171002 (Pfizer), K-877-302 (Kowa), Sci-B-Vac-002 (VBI), ZP4207-16136 (Zealand), I8H-MC-BDCB (Eli Lilly), DBC-15SWATCH05 (BD), BRB-018-001 (BirdRockBio), 2 (FNIH), XSGP-301 (Xeris), XSGP-303 (Xeris), ZP4207-16137 (Zealand), XSGP-304 (Xeris), XSMP-204 (Xeris), I8B-MC-ITSA (Eli Lilly), FIT Untethered (LMC Diabetes & Endocrinology), OBS16040 (Sanofi), T1-Dexi (JAEB), EFC14828 (Sanofi), PTL903076 (Dexcom), ZP4207-17084 (Zealand), etc. |
| 1997-2015 | 264 Clinical Trials – sponsors including Pfizer, Novo Nordisk Boehringer Ingelheim, Sanofi, GSK, Takeda, Eli Lilly, Roche, Novartis, AstraZeneca, Bristol-Myers Squibb  |

\* >42 Publications